Post-exposure therapy with human butyrylcholinesterase following percutaneous VX challenge in guinea pigs

Clinical Toxicology

Volumn 49, Issue 4, 2011, Pages 287-297

  Mumford, Helen ^a   Price, Matthew E ^a   Lenz, David E ^b   Cerasoli, Douglas M ^b  

^a Department of Biomedical Sciences ^*  (United Kingdom)

^b US ARMY MEDICAL RESEARCH INSTITUTE OF CHEMICAL DEFENSE   (United States)

Author keywords

Bioscavenger; Guinea pig; Medical countermeasures; Nerve agent; Percutaneous; VX

Indexed keywords

CHOLINESTERASE; HUMAN BUTYRYLCHOLINESTERASE; METHYLPHOSPHONOTHIOIC ACID S (2 DIISOPROPYLAMINOETHYL) O ETHYL ESTER; UNCLASSIFIED DRUG;

ABRASION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY TEMPERATURE; BODY WEIGHT; BRADYCARDIA; CONTROLLED STUDY; DRUG INTOXICATION; ELECTROCARDIOGRAPHY MONITORING; ELECTROENCEPHALOGRAM; ENZYME ACTIVITY; ERYTHROCYTE; GUINEA PIG; HEART ARRHYTHMIA; HEART RATE; HUMAN; HYPERINFLATION; HYPOTHERMIA; INTESTINE INTUSSUSCEPTION; LACRIMATION; LETHALITY; LOCOMOTION; LUNG HEMORRHAGE; MALE; NONHUMAN; POST EXPOSURE PROPHYLAXIS; SALIVATION; SEIZURE; STOICHIOMETRY; SURVIVAL; TELEMETRY; TREMOR;

ACETYLCHOLINESTERASE; ADMINISTRATION, CUTANEOUS; ANIMALS; BUTYRYLCHOLINESTERASE; CHEMICAL WARFARE AGENTS; GUINEA PIGS; HUMANS; MALE; ORGANOTHIOPHOSPHORUS COMPOUNDS;

ANIMALIA; CAVIA;

EID: 79956137356     PISSN: 15563650     EISSN: 15569519     Source Type: Journal    
DOI: 10.3109/15563650.2011.568944     Document Type: Article

References (31)

1. Newmark J. Nerve agents. Neurologist 2007; 13:20-32. (Pubitemid 46095581)
2. Wetherell J, Price M, Mumford H. A novel approach for medical countermeasures to nerve agent poisoning in the guinea-pig. Neurotoxicology 2006; 27:485-491. (Pubitemid 43867780)
3. Masson P, Lockridge O. Butyrylcholinesterase for protection from organophosphorus poisons: catalytic complexities and hysteretic behavior. Arch Biochem Biophys 2010; 494:107-120.
4. Lenz DE, Yeung D, Smith JR, Sweeney RE, Lumley LA, Cerasoli DM. Stoichiometric and catalytic scavengers as protection against nerve agent toxicity: a mini review. Toxicology 2007; 233:31-39. (Pubitemid 46505351)
5. Bjarnason S, Mikler J, Hill I, Tenn C, Garrett M, Caddy N, Sawyer TW. Comparison of selected skin decontaminant products and regimens against VX in domestic swine. Hum Exp Toxicol 2008; 27:253-261.
6. Duncan EJS, Brown A, Lundy P, Sawyer TW, Hamilton M, Hill I, Conley JD. Site-specific percutaneous absorption of methyl salicylate and VX in domestic swine. J Appl Toxicol 2002; 22:141-148. (Pubitemid 34591511)
7. Hamilton MG, Hill I, Conley J, Sawyer TW, Caneva DC, Lundy PM. Clinical aspects of percutaneous poisoning by the chemical warfare agent VX: effects of application site and decontamination. Mil Med 2004; 169:856-862. (Pubitemid 40797190)
8. Dalton CH, Hattersley IJ, Rutter SJ, Chilcott RP. Absorption of the nerve agent VX (O-ethyl-S-[2(di-isopropylamino)ethyl] methyl phosphonothioate) through pig, human and guinea pig skin in vitro. Toxicol in Vitro 2006; 20:1532-1526.
9. Mumford H, Price ME, Wetherell JR. A novel approach to assessing percutaneous VX poisoning in the conscious guinea-pig. J Appl Toxicol 2008; 28:694-702. (Pubitemid 352009761)
10. Vale JA, Rice P, Marrs TC. Managing civilian casualties affected by nerve agents. In: Marrs TC, Maynard RL, Sidell FR, eds. Chemical Warfare Agents: Toxicology and Treatment. Chichester: John Wiley & Sons, Ltd; 2007:249-260.
11. Mumford H, Price ME, Cerasoli DM, Teschner W, Ehrlich H, Schwarz HP. Efficacy and physiological effects of human butyrycholinesterase as a post-exposure therapy against percutaneous poisoning by VX in the guinea-pig. Chem Biol Interact 2010; 187:304-308.
12. Kolarich D, Weber A, Pabst M, Stadlmann J, Teschner W, Ehrlich H. Glycoproteornic characterization of butyrylcholinesterase from human plasma. Proteomics 2008; 8:254-263. (Pubitemid 351212325)
13. Weber A, Butterweck H, Mais-Paul U, Teschner W, Lei L, Muchitsch EM. Biochemical, molecular and preclinical characterization of a double-virus-reduced human butyrylcholinesterase preparation designed for clinical use. Vox Sang 2011; 100:285-297.
14. Wetherell JR. Continuous administration of low-dose rates of physostigmine and hyoscine to guinea-pigs prevents the toxicity and reduces the incapacitation produced by soman poisoning. J Pharm Pharmacol 1994; 46:1023-1028.
15. Wetherell J, Hall T, Passingham S. Physostigmine and hyoscine improves protection against the lethal and incapacitating effects of nerve agent poisoning in the guinea-pig. Neurotoxicology 2002; 23:341-349.
16. Wetherell J, Price M, Mumford H, Armstrong S, Scott L. Development of next generation medical countermeasures to nerve agent poisoning. Toxicology 2007; 233:120-127. (Pubitemid 46509685)
17. Lenz DE, Maxwell DM, Koplovitz I, Clark CR, Capacio BR, Cerasoli DM. Protection against soman or VX poisoning by human butyrylcholinesterase in guinea pigs and cynomolgus monkeys. Chem Biol Interact 2005; 157:205-210. (Pubitemid 41757652)
18. Tenn CC, Mikler JR, Hill I, Weatherby K, Garrett M, Caddy N. Recombinant human butyrylcholinesterase as a therapeutic agent to counteract the effects of VX toxicity in domestic swine. J Med Chem Def 2008; 6.
19. Lenz DE, Clarkson ED, Schultz SM, Cerasoli DM. Butyrylcholinesterase as a therapeutic drug for protection against percutaneous VX. Chem Biol Interact 2010; 187:249-252.
20. Sidell FR. A history of human studies with nerve agents by the UK and USA. In: Marrs TC, Maynard RL, Sidell FR, eds. Chemical Warfare Agents: Toxicology and Treatment. 2nd ed. Chichester: John Wiley & Sons, Ltd; 2007:223-239.
21. van der Schans MJ, Lander BJ, van der Wiel H, Langenberg JP, Benschop HP. Toxicokinetics of the nerve agent ('/7)-VX in anesthetized and atropinized hairless guinea pigs and marmosets after intravenous and percutaneous administration. Toxicol Appl Pharmacol 2003; 191:48-62. (Pubitemid 36959963)
22. Dorandeu F, Foquin A, Briot R, Delacour C, Denis J, Alonso A. An unexpected plasma cholinesterase activity rebound after challenge with a high dose of the nerve agent VX. Toxicology 2008; 248:151-157.
23. Joosen MJA, van der Schans MJ, van Helden HPM. Percutaneous exposure to VX: clinical signs, effects on brain acetylcholine levels and EEG. Neurochem Res 2008; 33:308-317.
24. Shih TM, McDonough JH. Efficacy of biperiden and atropine as anticonvulsant treatment for organophosphorus nerve agent intoxication. Arch Toxicol 2000; 74:165-172. (Pubitemid 30351392)
25. Sun W, Doctor BP, Saxena A. Safety and pharmacokinetics of human serum butyrylcholinesterase in guinea pigs. Chem Biol Interact 2005; 157:428-429. (Pubitemid 41757719)
26. Sun W, Doctor BP, Lenz DE, Saxena A. Long-term effects of human butyrylcholinesterase pretreatment followed by acute soman challenge in cynomolgus monkeys. Chem Biol Interact 2008; 175:428-430.
27. Katos AM, Conti ML, Moran TS, Gordon RK, Doctor BP, Sciuto AM. Abdominal bloating and irritable bowel syndrome like symptoms following microinstillation inhalation exposure to chemical warfare nerve agent VX in guinea pigs. Toxicol Ind Health 2007; 23:231-240. (Pubitemid 350242398)
28. Che MM, Conti M, Chanda S, Boylan M, Sabnekar P, Rezk P. Postexposure treatment with nasal atropine methyl bromide protects against microinstillation inhalation exposure to sarin in guinea pigs. Toxicol Appl Pharmacol 2009; 239:251-257.
29. Worek F, Kirchner T, Szinicz L. Effect of atropine and bispyridinium oximes on respiratory and circulatory function in guinea-pigs poisoned by sarin. Toxicology 1995; 95:123-133.
30. Zhuang J, Xu F, Campen MJ, Zhang C, Pena-Philippides JC, Sopori ML. Inhalation of the nerve gas sarin impairs ventilatory responses to hypercapnia and hypoxia in rats. Toxicol Appl Pharmacol 2008; 232:440-447.
31. Eddleston M, Mohamed F, Davies JOJ, Eyer P, Worek F, Sheriff MHR, Buckley NA. Respiratory failure in acute organophosphorus pesticide self-poisoning. QJM: An Int J Med 2006; 99:513-522. (Pubitemid 44304836)